[A patient diagnosed with MOGAD after COVID-19 - A case report]

MOGAD (myelin oligodendrocyte glycoprotein antibody disease) is a newly defined inflammatory condition of the central nervous system. The presence of MOG antibodies holds a key role in the identification of the disease, as the detection of these anitbodies points to an inflammatory state with a distinct clinical presentation, specific radiological and laboratory findings, different course and prognosis as well as separate treatment considerations. Simultaneously, during the last two years healthcare worldwide has focused a large part of its resources on the management of COVID-19 patients. The long-term health effects of the infection are still unknown, but a large part of its manifestations are similar to those already seen in other viral infections.  A significant percentage of patients who develop demyelinating disorders in the central nervous system presents an acute post-infectious inflammatory process (ADEM).  Here we report the case of a young woman who presented a clinical picture compatible with ADEM after SARS-CoV-2 infection that led to a MOGAD diagnosis.